TSL-B2276-1-01: A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors (clinicaltrials.gov) - Apr 7, 2026 - P1/2 | N=19 | Completed | Sponsor: Tasly Pharmaceutical Group Co., Ltd | Recruiting ➔ Completed | N=132 ➔ 19 | Trial completion date: Dec 2027 ➔ Dec 2025 | Trial primary completion date: Dec 2026 ➔ Jun 2025
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Endometrial Cancer • Epithelial Ovarian Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR
|